Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.07. | Milestone Pharmaceuticals Launches Public Offering To Support Etripamil Development | 4 | RTTNews | ||
11.07. | Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge | 3 | Benzinga.com | ||
11.07. | Why Is Milestone Pharmaceuticals Stock Plunging On Friday? | 1 | Benzinga.com | ||
MILESTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
11.07. | Milestone Pharmaceuticals plunges after pricing $52.5M offering | 3 | Seeking Alpha | ||
11.07. | Milestone Pharmaceuticals prices $52.5 million public offering | 2 | Investing.com | ||
11.07. | Milestone Pharmaceuticals stock plunges on public offering announcement | 4 | Investing.com | ||
11.07. | Kapitalerhöhung angekündigt: Aktie von Milestone Pharmaceuticals bricht ein | 3 | Investing.com Deutsch | ||
11.07. | Milestone Pharmaceuticals proposes capital raise via securities offering | 1 | Seeking Alpha | ||
11.07. | Milestone Pharmaceuticals announces public offering of shares and warrants | 3 | Investing.com | ||
11.07. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.07. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST (etripamil) Nasal Spray | 236 | GlobeNewswire (Europe) | New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone®... ► Artikel lesen | |
17.06. | Milestone Pharmaceuticals resubmits Cardamyst filing after FDA response | 4 | Investing.com | ||
16.06. | Milestone Pharma Announces Submission Of Its Response To CRL Regarding NDA For CARDAMYST | 1 | RTTNews | ||
16.06. | Milestone Pharmaceuticals submits response to FDA for PSVT drug | 3 | Investing.com | ||
12.06. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 2 | SEC Filings | ||
14.05. | Milestone Pharmaceuticals GAAP EPS of -$0.31 misses by $0.13 | 10 | Seeking Alpha | ||
14.05. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update | 485 | GlobeNewswire (Europe) | Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
14.05. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.05. | Milestone Pharmaceuticals Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
01.04. | TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty | 4 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 29,035 | -0,31 % | Bayer-Partner Orion: AKTIONÄR-Tipp schießt auf neues Rekordhoch | Die Geschäfte beim finnischen Pharma-Konzern Orion laufen weiterhin rund. Dass sich das Unternehmen auf einem guten Wachstumskurs befindet, hat die erhöhte Jahresprognose Anfang Juli bereits gezeigt.... ► Artikel lesen | |
NOVO NORDISK | 60,63 | +0,71 % | Hims & Hers nach Aus mit Novo Nordisk: "Erhöhtes Risiko von Rechtsstreitigkeiten" | Wie gewonnen, so zerronnen: Zunächst entfachte die umfangreiche Zusammenarbeit zwischen dem Telehealth-Unternehmen Hims & Hers und dem Biopharma-Riesen Novo Nordisk jede Menge Euphorie. Doch dann kam... ► Artikel lesen | |
PFIZER | 21,285 | -1,32 % | BioNTech SE: Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an LP.8.1 angepassten COVID-19-Impfstoff in der Europäischen Union | Daten zeigten, dass der an LP.8.1 angepasste COVID-19-Impfstoff verglichen mit den COVID-19-Impfstoffformulierungen 2024-2025 eine verbesserte Immunantwort gegen derzeit vorherrschende und neu auftretende... ► Artikel lesen | |
GILEAD SCIENCES | 97,30 | +1,05 % | Gilead Sciences, Inc.: Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention | - If Approved, Lenacapavir Would Be the First and Only Twice-Yearly HIV PrEP Option in the European Union - - Positive Opinion Also Received for EMA's EU-M4all Procedure, Designed to Facilitate... ► Artikel lesen | |
MERCK & CO | 72,00 | +0,56 % | Schlüssel-Technologie im Kampf gegen Krebs? Merck & Co., Vidac Pharma, AstraZeneca | Wissen Sie, was aerobe Glykolyse ist? Nein? Schon mal etwas vom Warburg-Effekt gehört? Beide Begriffe beschreiben dasselbe Phänomen. Es geht darum, dass Krebszellen selbst bei ausreichender Sauerstoffversorgung... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 404,80 | +0,73 % | Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis | ||
EYEPOINT PHARMACEUTICALS | 9,258 | +3,86 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
BAUSCH HEALTH | 5,670 | -1,60 % | Bausch Health Companies Inc.: Bausch Health Announces the Appointment of Two New Members to Its Board of Directors | LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and... ► Artikel lesen | |
ROCKET LAB | 40,600 | -0,98 % | Rocket Lab: A Parabolic Run Meets a Healthy Pullback | ||
ASSEMBLY BIOSCIENCES | 15,750 | +0,64 % | Assembly Biosciences: ABI-4334 erreicht Studienziel - Gilead-Entscheidung steht bevor | Assembly Biosciences (WKN: A402CB) liefert weiter ab: Mit ABI-4334 fällt der erste wichtige Readout dieses Jahres positiv aus. Das HBV-Asset galt als das unsicherste im Portfolio. Die Aktie liebäugelt... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 5,600 | 0,00 % | Astria Therapeutics, Inc.: Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress | -- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction -- -- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction - -- Well-Tolerated with a Favorable Safety Profile -- --... ► Artikel lesen | |
NEWRON PHARMACEUTICALS | 7,670 | +2,40 % | Edison Group: Edison Issues Report on Newron Pharmaceuticals (NWRN) | London, United Kingdom--(Newsfile Corp. - July 9, 2025) - Edison issues report on Newron Pharmaceuticals (SIX: NWRN).Newron Pharmaceuticals is making significant headway in progressing its drug candidate... ► Artikel lesen | |
OPKO HEALTH | 1,169 | -1,50 % | OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) | ||
ALTIMMUNE | 3,607 | +3,32 % | Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect | ||
LIGAND PHARMACEUTICALS | 113,00 | 0,00 % | Ligand Pharmaceuticals: Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 |